A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction. An Editorial from a Legal Perspective

International Review of Neurobiology

Volumn 126, Issue , 2016, Pages 15-38

  Andraka Christou, B ^a  

^a NONE   (United States)

Author keywords

Addiction; Drug dependence; Medication assisted treatment; Pharmaceutical incentives; Research and development

Indexed keywords

BUPRENORPHINE; IBUDILAST; METHADONE; NALTREXONE; TOPIRAMATE;

ALCOHOLISM; ARTICLE; CLINICAL STUDY; COCAINE DEPENDENCE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; LAW; METHADONE TREATMENT; METHAMPHETAMINE DEPENDENCE; OPIATE ADDICTION; PHASE 2 CLINICAL TRIAL (TOPIC); POLITICS; PRIORITY JOURNAL; TAX; WITHDRAWAL SYNDROME; ANIMAL; LEGISLATION AND JURISPRUDENCE; MOTIVATION; SUBSTANCE-RELATED DISORDERS; TRENDS;

ANIMALS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MOTIVATION; SUBSTANCE-RELATED DISORDERS;

EID: 84960539377     PISSN: 00747742     EISSN: 21625514     Source Type: Book Series    
DOI: 10.1016/bs.irn.2016.02.003     Document Type: Chapter

References (102)

1. Amato L., Davoli M., Perucci C., Ferri M., Faggiano F., et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 2005, 28:321-329.
2. American Association for the Treatment of Opioid Dependence, Inc. AAOTD guidelines for using naltrexone (vivitrol) in OTPs Retrieved from. http://www.aatod.org/policies/policy-statements/aatod-guidelines-for-using-naltrexone-vivitrol-in-otps/.
3. American Society of Addiction Medicine Advancing access to addiction medications Retrieved from. http://www.asam.org/docs/default-source/advocacy/aaam_implications-for-opioid-addiction-treatment_final.
4. Amundson K., Zajicek A., Hunt V. Pathologies of the poor: What do the War on drugs and welfare reform have in common?. Journal of Sociology and Social Welfare 2014, XLI(1):5-28.
5. Bartfai T., Lees G. The future of drug discovery: Who decides which diseases to treat? 2013, Elsevier, Oxford, UK.
6. Birnbaum H.G., White A.G., Schiller M., Waldman T., Cleveland J.M., Roland C.L. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Medicine 2011, 12(4):657-667.
7. Boldt R. The "tomahawk" and the "healing balm": Drug treatment courts in theory and practice. University of Maryland Law Journal of Race, Religion, Gender, and Class 2010, 9(1):45-71.
8. Boldt R. The "tomahawk" and the "healing balm": Drug treatment courts in theory and practice. University of Maryland Law Journal of Race, Religion, Gender, and Class 2010, 10(45):59-60.
9. Boozang P., Bachrach D., Detty A. Coverage and delivery of adult substance abuse services in medicaid managed care 2014, Medicaid Managed Care Information Resource Center, Centers for Medicare and Medicaid Services, Technical Assistance Brief 2 (2).
10. Caplehorn J.R. A comparison of abstinence-oriented and indefinite methadone maintenance treatment. The International Journal of Addictions 1994, 11:1361-1375.
11. Caplehorn J.R., MacNeil D.R., Kleinbaum D.G. Clinic policy and retention in methadone maintenance. International Journal of Addictions 1993, 28(1):73-89.
12. CBS News Merck closing 8 plants, 8 research sites Retrieved from. http://www.cbsnews.com/news/merck-closing-8-plants-8-research-sites/.
13. Chen L.H., Hedegaard H., Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011 2014, Centers for Disease Control and Prevention, NCHS Data Brief (No. 166). Retrieved from. http://www.cdc.gov/nchs/data/databriefs/db166.htm.
14. Cherkis J. Dying to be free. The Huffington Post 2015, Retrieved from. http://projects.huffingtonpost.com/dying-to-be-free-heroin-treatment.
15. Chicago Business Health care overhaul will add coverage for millions of addicts Retrieved from. http://www.chicagobusiness.com/article/20130911/NEWS03/130919947/health-care-overhaul-will-add-coverage-for-millions-of-addicts.
16. Childress S. Dr. Charles Knirsch: "These are not ruthless decisions". Frontline, PBS News. 2013, Retrieved from. http://www.pbs.org/wgbh/pages/frontline/health-science-technology/hunting-the-nightmare-bacteria/dr-charles-knirsch-these-are-not-ruthless-decisions/.
17. Consolidated Appropriations Act, 2016 (2015). Public Law No. 114-113.
18. Corrigan P. How stigma interferes with mental health care. American Psychologist 2004, 59(7):614-625.
19. Crimm N. A tax proposal to promote pharmacologic research, to encourage conventional prescription drug innovation and improvement, and to reduce product liability claims. Wake Forest Law Review 1994, 29:1007-1099.
20. Crow J. Non-profit pharma. Chemistry World 2013, Retrieved from. http://www.rsc.org/chemistryworld/2013/09/pharma-medicinal-chemistry-non-profit-rare-disease.
21. Drug Free Kentucky Northern Kentucky's collective response to the heroin epidemic Retrieved from. http://drugfreenky.org/wp-content/uploads/2013/11/Northern-Kentuckys-Collective-Response-Final.pdf.
22. European Commission Regulation [EC] No 141/2000 of the European parliament and of the council 1999, Article 8, § 2.
23. Federal Opioid Treatment Standards (2003). 42 C.F.R. § 8.12 (h)(3)(i)(II).
24. Food and Drug Administration Amendment Act (2007). Public Law 110-85, 121 Stat. 823 § 1102, codified as amended at 21 U.S.C. 301.
25. Food and Drug Modernization Act (1997). Pub. L. No. 105-115, § 111, 111 Stat. 2296, codified as amended at 21 U.S.C. § 351.
26. Gill V. The rise of the biologic. Royal Society of Chemistry. 2015, Retrieved from. http://www.rsc.org/chemistryworld/Issues/2008/January/TheRiseOfBiologic.asp.
27. Hamming L. The promise of priority review vouchers as a legislative tool to encourage drugs for neglected diseases. Duke Law & Technology Review 2013, 11:390-412.
28. Herman J., Stancliff S., Langrod J. Methadone maintenance treatment: A review of historical and clinical issues. The Mount Sinai Journal of Medicine 2000, 67(5):347. 361.
29. Hesse M., Pederson M. Easy-access services in low-threshold opiate agonist maintenance. International Journal of Mental Health and Addiction 2008, 6:316.
30. Hoffman D. What's driving the pharmaceutical industry's drug development process?. Philly News. 2014, Retrieved from. http://www.philly.com/philly/blogs/healthcare/Whats-driving-the-pharmaceutical-industrys-drug-development-process.html.
31. Hu M., Schultz K., Sheu J., Tschopp D. The innovation gap in pharmaceutical drug discovery and new models for R&D success 2007, Kellog School of Management, Retrieved from. http://www.kellogg.northwestern.edu/biotech/faculty/articles/newrdmodel.pdf.
32. Jackson C. Comment: Pharmaceutical product liability may be hazardous to your health: A no-fault alternative to concurrent regulation. American University Law Review 1992, 42:199.
33. Johnson K.W., Matsuda K., Iwaki Y. Ibudilast for the treatment of drug addiction and other neurological conditions. Clinical Investigation 2014, 4(3):269-279.
34. Jones C.M., Campopiano M., Baldwin G., McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health 2015, 105(8):e55-e63.
35. Kastelic A., Pont J., Stöver H. Opioid substitution treatment in custodial settings: A practical guide 2008, United Nations Office on Drugs and Crime/World Health Organization, Retrieved from, (Last visited Jan. 4, 2016). https://www.unodc.org/documents/hiv-aids/OST_in_Custodial_Settings.pdf.
36. Kjome K., Moeller F. Long-acting injectable naltrexone for the management of patients with opioid dependence. Substance Abuse: Research and Treatment 2011, 5:1-9.
37. Knudsen H.K., Ducharme L.J., Roman P.M., Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment 2005, 29:95-106.
38. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., et al. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. The Lancet 2001, 377(9776):1506-1513.
39. LaMattina J. Pharma R&D cuts hurting U.S. competitive standing. Forbes. 2014, Retrieved from. http://www.forbes.com/sites/johnlamattina/2014/01/03/pharma-rd-cuts-hurting-u-s-competitive-standing/.
40. Magura S., Rosenblum A., Lewis C., Joseph H. The effectiveness of in-jail methadone maintenance. Journal of Drug Issues 1993, 23:75-99.
41. Management Centre Europe New opportunities and strategies in the pharmaceutical industry. The Executive Issue 2012, 38(6). Retrieved from. http://www.mce-ama.com/executive-issue-38-pharma-industry-2012/.
42. Matusow H., et al. Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. Journal of Substance Abuse Treatment 2013, 44(5):473-480.
43. Maxwell J. The pain reliever and heroin epidemic in the United States: Shifting winds in the perfect storm. Journal of Addictive Diseases 2015, 34(2-3):127-140.
44. Miles K. Meth addiction cure: UCLA tests ibudilast on human addicts. The Huffington Post 2013, Retrieved from. http://www.huffingtonpost.com/2013/04/03/meth-addiction-cure-ucla-ibudilast_n_2863126.html.
45. Mittra J. Life science innovation and the restructuring of the pharmaceutical industry: Merger, acquisition and strategic alliance behavior of large firms. Technology Analysis and Strategic Management 2007, 19(3):279. 282-283.
46. Mundasad S. The end of drug discovery. Health, BBC News. 2012, Retrieved from. http://www.bbc.com/news/health-18095669.
47. National Association of Drug Court Professionals Resolution of the board of directors on the availability of medically assisted treatment (M.A.T.) for addiction in drug courts 2011, Retrieved from. http://www.nadcp.org/sites/default/files/nadcp/NADCP%20Board%20Statement%20on%20MAT.pdf.
48. National Association of Drug Court Professionals What are drug courts? Retrieved from. http://www.nadcp.org/learn/what-are-drug-courts.
49. Nicholls L., Bragaw L., Ruetsch C. Supplement opioid dependence treatment and guidelines. Supplement to Journal of Managed Care Pharmacy 2010, 16(1-b):S14-S21.
50. Nicosia N., Pacula R., Kilmer B., Lundberg R., Chiesa J. The economic cost of methamphetamine abuse in the U.S 2005, The Rand Corporation, Retrieved from. http://www.rand.org/pubs/monographs/MG829.html.
51. Nunn A., Zaller N., Dickman S., Trimbur C., Nijhawan A., et al. Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug and Alcohol Dependence 2009, 105(1-2):83-88.
52. Offit P.A. Why are pharmaceutical companies gradually abandoning vaccines?. Health Affairs 2005, 24(3):622-630.
53. O'Reilly M. Case brief: The failures of project bioshield & congressional attempts to remedy it. DePaul Journal of Health Care 2007, 10:503-511.
54. Orphan Drug Act (1983). Pub. L. No. 97-414, 96 Stat. 2049, codified as amended at 21 U.S.C., 26 U.S.C., 35 U.S.C., 42 U.S.C.
55. Pharmaceutical Research and Manufacturers of America 2015 Profile biopharmaceutical research industry Retrieved from. http://www.phrma.org/sites/default/files/pdf/2014_PhRMA_PROFILE.pdf.
56. Plumridge H. Drug makers tiptoe back into antibiotic R&D. The Wall Street Journal 2014, Retrieved from. http://www.wsj.com/articles/SB10001424052702303465004579322601579895822.
57. Project Bioshield Act (2004). Pub. L. No. 108-276, 118 Stat. 835 § 2(a), codified as amended at 42 U.S.C. 243; Pub. L. No. 110-85, 121 Stat. 823, codified as amended at 21 U.S.C. & 42 U.S.C.
58. Querido J. Imatinib-The dawn of targeted treatments 2012, Cancer Research UK, Retrieved from. http://scienceblog.cancerresearchuk.org/2012/10/25/imatinib-the-dawn-of-targeted-treatments/.
59. Rin-Laures L.-H., Janofsky D. Recent developments concerning the Orphan Drug Act. Harvard Journal of Law & Technology 1991, 4:269-297.
60. Rosenblatt R., Andrilla C.H., Catlin M., Larson E.H. Geographic and specialty distribution of U.S. physicians trained to treat opioid use disorder. Annals of Family Medicine 2015, 13(1):23-26.
61. Sabatier P. Theories of the policy process 2007, Westview Press, New York, NY. 2nd ed.
62. Scannell J., Blanckley A., Boldon H., Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews. Drug Discovery 2012, 11:191-200.
63. Science Daily Study reveals first effective medicine to treat cocaine dependence Retrieved from. http://www.sciencedaily.com/releases/2013/10/131025113741.htm.
64. Segalat L. Loss-of-function genetic diseases and the concept of pharmaceutical targets. Orphanet Journal of Rare Disease 2007, 2:30.
65. Sharma A., Jacob A., Tandon M., Kumar D. Orphan drug: Development trends and strategies. Journal of Pharmacy and Bioallied Sciences 2010, 290(4):290-299.
66. Stotts A., Carrie Dodrill C., Kosten T. Opioid dependence treatment: Options in pharmacotherapy. Expert Opinion on Pharmacotherapy 2009, 10(11):1727.
67. Substance Abuse and Mental Health Services Administration An introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. Advisory 2012, 11(1). Retrieved from. https://store.samhsa.gov/shin/content/SMA12-4682/SMA12-4682.pdf.
68. Substance Abuse and Mental Health Services Administration Adult drug courts and medication-assisted treatment for opioid dependence. In Brief 2014, 8(1). Retrieved from. http://dsamh.utah.gov/pdf/SAMHSA%20MAT.pdf.
69. Thaul S. FDA fast track and priority review programs 2008, Congressional Research Service, Retrieved from. https://www.fas.org/sgp/crs/misc/R41983.pdf.
70. The National Alliance of Advocates for Buprenorphine Treatment What is withdrawal? Retrieved from. http://www.naabt.org/faq_answers.cfm?ID=16.
71. Trautmann S., Wittchen H.-U. An analysis of German settings providing opioid maintenance therapy. Substance Use and Misuse 2012, 47:22. 23.
72. UNAIDS, Joint United Nations Programme on HIV/AIDS Key programmes to reduce stigma and discrimination and increase access to justice in national HIV responses Retrieved from. http://www.unaids.org/sites/default/files/media_asset/Key_Human_Rights_Programmes_en_May2012_0.pdf.
73. United Nations, Office on Drugs and Crime, World Health Organization (2009). Discussion paper: Principles of drug dependence treatment. https://www.unodc.org/documents/drug-treatment/UNODC-WHO-Principles-of-Drug-Dependence-Treatment-March08.pdf.
74. United States Department of Health and Human Services [USDHHS] U.S. Food and Drug Administration. Priority Review. 2014, Retrieved from. http://www.fda.gov/ForPatients/Approvals/Fast/ucm405405.htm.
75. United States Department of Health and Human Services [USDHHS] 2014, Retrieved from. http://store.samhsa.gov/shin/content//SMA14-4883/SMA14-4883.pdf.
76. United States Department of Health and Human Services [USDHHS] About buprenorphine treatment Retrieved from. http://buprenorphine.samhsa.gov/about.html.
77. United States Department of Health and Human Services [USDHHS] Executive summary: Opioid abuse in the U.S. and HHS actions to address opioid-drug related overdoses and deaths Retrieved from. http://aspe.hhs.gov/sp/reports/2015/OpioidInitiative/es_OpioidInitiative.pdf.
78. United States Department of Health and Human Services, Food and Drug Administration [USDHHS] Guidance for industry neglected tropical diseases of the developing world: Developing drugs for treatment or prevention Retrieved from. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm269221.pdf.
79. United States Department of Health and Human Services, National Institute on Drug Abuse [USDHHS] Are cocaine abusers at risk for contracting HIV/AIDS and hepatitis B and C? Retrieved from. http://www.drugabuse.gov/publications/research-reports/cocaine/are-cocaine-abusers-risk-contracting-hivaids-hepatitis-b-c.
80. United States Department of Health and Human Services, National Institute on Drug Abuse [USDHHS] What treatments are effective for cocaine abusers? Retrieved from. http://www.drugabuse.gov/publications/research-reports/cocaine/what-treatments-are-effective-cocaine-abusers.
81. United States Department of Health and Human Services, National Institute on Drug Abuse [USDHHS] What treatments are effective for methamphetamine abusers? Retrieved from. http://www.drugabuse.gov/publications/research-reports/methamphetamine/what-treatments-are-effective-methamphetamine-abusers.
82. United States Department of Health and Human Services, National Institute on Drug Abuse [USDHHS] What is the scope of methamphetamine abuse in the U.S.? Retrieved from. http://www.drugabuse.gov/publications/research-reports/methamphetamine/what-scope-methamphetamine-abuse-in-united-states.
83. United States Department of Health and Human Services, National Institute on Drug Abuse [USDHHS] What is the scope of cocaine use in the U.S.? Retrieved from. http://www.drugabuse.gov/publications/research-reports/cocaine/what-scope-cocaine-use-in-united-states.
84. United States Department of Health and Human Services, National Institute on Drug Abuse [USDHHS] What are the long-term effects of methamphetamine abuse? Retrieved from. http://www.drugabuse.gov/publications/research-reports/methamphetamine/what-are-long-term-effects-methamphetamine-abuse.
85. United States Department of Health and Human Services, National Institute on Drug Abuse [USDHHS] Principles of drug addiction: A research-based guide. What is drug addiction treatment? Retrieved from. http://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/frequently-asked-questions/what-drug-addiction-treatment.
86. United States Department of Health and Human Services, National Institutes of Health [USDHHS] About NCATS, budget Retrieved from. http://www.ncats.nih.gov/about/budget/budget.html.
87. United States Department of Health and Human Services, National Institutes of Health [USDHHS] Trends & Statistics Retrieved from. http://www.drugabuse.gov/related-topics/trends-statistics.
88. United States Department of Health and Human Services, Office of the Inspector General [USDHHS] The Orphan Drug Act implementation & impact Retrieved from. https://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf.
89. United States Department of Health of Health and Human Services, National Institute on Drug Abuse [USDHHS] What are the long-term effects of cocaine use? 2010, National Institute on Drug Abuse, Retrieved from. http://www.drugabuse.gov/publications/research-reports/cocaine/what-are-long-term-effects-cocaine-use.
90. United States Food and Drug Administration Fast track, breakthrough therapy, accelerated approval, priority review Retrieved from. http://www.fda.gov/ForPatients/Approvals/Fast/default.htm.
91. United States National Institutes of Health, ClinicalTrials.gov Trial of ibudilast for methamphetamine dependence (IBUD ph II) Retrieved from. https://clinicaltrials.gov/ct2/show/NCT01860807.
92. United Therapeutics United therapeutics corporation agrees to sell priority review voucher to AbbVie for $350 million Retrieved from. http://ir.unither.com/releasedetail.cfm?ReleaseID=928100.
93. Vestal C. How severe is the shortage of substance abuse specialists? April 1, 2015, The Pew Charitable Trusts, Retrieved from. http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2015/4/01/how-severe-is-the-shortage-of-substance-abuse-specialists.
94. Volkow N.D. America's dependence to opioids: Heroin and prescription drug abuse 2014, U.S. Department of Health and Human Services, National Institute on Drug Abuse, Retrieved from. http://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2015/americas-addiction-to-opioids-heroin-prescription-drug-abuse.
95. Volkow N.D., Li T.-K. Drug addiction: The neurobiology of behavior gone awry. Nature Reviews. Neuroscience 2004, 5(963):969.
96. Walley A., Alperen J., Cheng D., Botticelli M., Castro-Donlan C., Samet J., et al. Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Internal Medicine 2008, 23(9):1393-1398.
97. Wang J., Qian W., Liu J., Zhao J., Yu P., et al. Effect of methamphetamine on the microglial damage: Role of potassium channel Kv1. PLoS One 2004, 9(2):7-9.
98. Weisman R. Research cuts ripple across biopharma sector. Boston Globe 2015, Retrieved from. http://www.bostonglobe.com/business/2015/03/18/some-fear-wave-biopharma-research-cuts-could-slow-progress-fighting-infectious-diseases/10lDVFIuUAJs9oLrqA3AIO/story.html.
99. White W., et al. Coparticipation in 12-step mutual aid groups and methadone maintenance treatment: A survey of 322 patients. Journal of Groups in Addiction & Recovery 2013, 8(4):294-308.
100. Willenbring M., Hagedorn H., Postier A. Variations in evidence-based clinical practices in nine United States veterans administration opioid agonist therapy clinics. Drug and Alcohol Dependence 2004, 75(1):97-106.
101. Woodall A., Morgan C., Sloan C., Howard L. Barriers to participation in mental health research: Are there specific gender, ethnicity, and age related barriers?. BMC Psychiatry 2010, 10:103.
102. World Health Organization Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence Retrieved from. http://www.who.int/substance:abuse/publications/opioid_dependence:guidelines.pdf.